EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

  1. Rosenberg, J.E.
  2. Powles, T.
  3. Sonpavde, G.P.
  4. Loriot, Y.
  5. Duran, I.
  6. Lee, J.-L.
  7. Matsubara, N.
  8. Vulsteke, C.
  9. Castellano, D.
  10. Mamtani, R.
  11. Wu, C.
  12. Matsangou, M.
  13. Campbell, M.
  14. Petrylak, D.P.
Revue:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Année de publication: 2023

Type: Article

DOI: 10.1016/J.ANNONC.2023.08.016 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus